Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer?s disease

被引:27
作者
Zhang, Junrong [1 ]
Liu, Rui [2 ]
Zhang, Dechen [1 ]
Zhang, Zhixian [1 ]
Zhu, Jinming [2 ]
Xu, Li [1 ]
Guo, Yi [1 ]
机构
[1] Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn, Minist Educ,Natl Engn Lab AIDS Vaccine, Changchun 130012, Peoples R China
[2] Jilin Univ, China Japan Union Hosp, Changchun 130033, Peoples R China
基金
中国国家自然科学基金;
关键词
Nanopeptide; Alzheimer?s disease; Neuroprotection; Oxidative stress; Gold nanoparticles; OXIDATIVE STRESS; GLUTAMATE; BRAIN; ACTIVATION; MECHANISMS; APOPTOSIS; PATHWAYS; EXTRACT; RATS;
D O I
10.1016/j.colsurfb.2021.111584
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Nanopeptide assembled from peptide-anchored nanoparticles possess an enormous research potential in the field of cellular medicine and disease treatment. The aim of this study was to explore the neuroprotective effects of maize tetrapeptide anchored gold nanoparticles against L-glutamic acid-induced PC12 cell apoptosis and a murine Alzheimer?s disease model induced by aluminum chloride and D-galactose. The results revealed that the nanopeptide antioxidant inhibited intracellular ROS accumulation and promoted cell differentiation than that of maize bioactive tetrapeptide. Compared with untreated Alzheimer?s disease model mice, nanopeptide administration shortened the escape latency time in a water maze test and improved the movements in the autonomic activity test. After 16 days of nanopeptide administration, the central cholinergic system function of acetylcholine and cholineacetyltransferase were enhanced, and the level of acetylcholinesterase was reduced. It also increased superoxide dismutase and glutathione peroxidase activity in sera and hypothalami. Moreover, nanopeptide treatment upregulated cerebral nuclear factor erythroid 2-related factor 2 and heme-oxygenase-1 and downregulated kelch-like ECH-associated protein 1 relative to untreated Alzheimer?s disease model mice. Thus, the novel nanopeptide is expected to be used as the neuroprotective agent to prevent Alzheimer?s disease.
引用
收藏
页数:11
相关论文
共 44 条
  • [1] Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
  • [2] [Anonymous], 2008, PSYCHIATRY
  • [3] Carnosine and taurine treatments diminished brain oxidative stress and apoptosis in D-galactose aging model
    Aydin, A. Fatih
    Coban, Jale
    Dogan-Ekici, Isin
    Betul-Kalaz, Esra
    Dogru-Abbasoglu, Semra
    Uysal, Mujdat
    [J]. METABOLIC BRAIN DISEASE, 2016, 31 (02) : 337 - 345
  • [4] Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
    Bachurin, Sergey O.
    Bovina, Elena V.
    Ustyugov, Aleksey A.
    [J]. MEDICINAL RESEARCH REVIEWS, 2017, 37 (05) : 1186 - 1225
  • [5] Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline
    Ballinger, Elizabeth C.
    Ananth, Mala
    Talmage, David A.
    Role, Lorna W.
    [J]. NEURON, 2016, 91 (06) : 1199 - 1218
  • [6] Neurodegenerative diseases and oxidative stress
    Barnham, KJ
    Masters, CL
    Bush, AI
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) : 205 - 214
  • [7] Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics
    Butterfield, D. Allan
    Perluigi, Marzia
    Sultana, Rukhsana
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 545 (01) : 39 - 50
  • [8] OXIDATIVE STRESS, GLUTAMATE, AND NEURODEGENERATIVE DISORDERS
    COYLE, JT
    PUTTFARCKEN, P
    [J]. SCIENCE, 1993, 262 (5134) : 689 - 695
  • [9] Therapeutic targeting of the NRF2 and KEAP 1 partnership in chronic diseases
    Cuadrado, Antonio
    Rojo, Ana, I
    Wells, Geoffrey
    Hayes, John D.
    Cousins, Sharon P.
    Rumsey, William L.
    Attucks, Otis C.
    Franklin, Stephen
    Levonen, Anna-Liisa
    Kensler, Thomas W.
    Dinkova-Kostova, Albena T.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (04) : 295 - 317
  • [10] Farlow MR, 2008, DRUG SAFETY, V31, P577, DOI 10.2165/00002018-200831070-00003